Suppr超能文献

可切除非小细胞肺癌的新辅助化疗

Neoadjuvant chemotherapy for resectable non-small cell lung cancer.

作者信息

Finkelstein E J, Urschel J D, Takita H

机构信息

School of Medicine, State University of New York at Buffalo, USA.

出版信息

J Exp Clin Cancer Res. 1997 Dec;16(4):437-9.

PMID:9505221
Abstract

Surgical therapy remains the only curative treatment of localized non-small cell lung carcinoma (NSCLC). Yet, the results of surgical therapy leave much to be desired. Recently, neoadjuvant chemotherapy for Stage III NSCLC had become an accepted therapeutic modality. Accordingly, a question is raised regarding the feasibility of neoadjuvant chemotherapy in resectable NSCLC (Stage I and II). In this paper we report three patients, in chronological order, with localized NSCLC who were treated with neoadjuvant chemotherapy. Neoadjuvant chemotherapy was given to the first case with poor pulmonary functions. Decrease in size of the tumor made it possible for him to undergo a more conservative lung resection. In the second case, chemotherapy was given with a presumptive diagnosis of metastatic lung lesion. A good response was noted and, histologically, it was a primary lung cancer. In the third case, chemotherapy was given to a patient with obviously resectable lung carcinoma, and an excellent response was observed. According to the results, neoadjuvant chemotherapy for resectable NSCLC may be feasible and beneficial.

摘要

手术治疗仍然是局限性非小细胞肺癌(NSCLC)唯一的治愈性治疗方法。然而,手术治疗的结果仍有很大的改进空间。最近,Ⅲ期NSCLC的新辅助化疗已成为一种被认可的治疗方式。因此,对于可切除的NSCLC(Ⅰ期和Ⅱ期)进行新辅助化疗的可行性提出了一个问题。在本文中,我们按时间顺序报告了3例接受新辅助化疗的局限性NSCLC患者。第一例肺功能较差的患者接受了新辅助化疗。肿瘤大小的减小使他能够接受更保守的肺切除术。第二例患者在初步诊断为肺转移瘤时接受了化疗。观察到良好的反应,组织学检查显示为原发性肺癌。第三例患者患有明显可切除的肺癌,接受了化疗,并观察到极佳的反应。根据这些结果,可切除的NSCLC进行新辅助化疗可能是可行且有益的。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验